Model Medicines

Oral presentation unifies the respiratory and hepatic programs. The first-in-class, direct-acting, broad-spectrum, Thumb-1 polymerase inhibitor demonstrates single-agent activity against influenza, RSV, SARS-CoV-2, HCV, HBV, and HDV, including activity ag

MDL-001 is being positioned as a potential broad-spectrum oral antiviral, with reported preclinical activity across several viral families.

Closely held Model Medicines is spearheading the use of AI to model chemistry and human biology, empowering drug discovery and creating novel, best-in-class therapeutics for diseases with high unmet medical needs at unprecedented speed.

Machine learning has provided a means to accelerate early-stage drug discovery by combining molecule generation and filtering steps in a single architecture that leverages the experience and design preferences of medicinal chemists. However, designing mac

( 1 ) Lloyd, M. D. High-Throughput Screening for the Discovery of Enzyme Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 1074210772. https:doi.org10.1021 acs.jmedchem.0c00523.

Schrödinger's scientists used cutting-edge virtual screening with large-scale docking, achieving a double-digit hit rate across diverse protein targets.